Deals
Triton’s €2 Billion Sale of Pharmanovia Is Stalling
- PE firms have been struggling to close deals this year
- Triton has been discussing sale of Pharmanovia to Permira
This article is for subscribers only.
Triton’s plans to sell Pharmanovia are stalling over valuation, people familiar with knowledge of the matter said, in another sign that private equity firms are struggling to get deals over the line.
UK-based Triton has been running an auction process for the British specialty pharma business and seeking more than €2 billion ($2.2 billion) in a deal, according to the people.